ATE549350T1 - Neuropeptid-2-rezeptor-agonisten - Google Patents
Neuropeptid-2-rezeptor-agonistenInfo
- Publication number
- ATE549350T1 ATE549350T1 AT06830133T AT06830133T ATE549350T1 AT E549350 T1 ATE549350 T1 AT E549350T1 AT 06830133 T AT06830133 T AT 06830133T AT 06830133 T AT06830133 T AT 06830133T AT E549350 T1 ATE549350 T1 AT E549350T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropeptide
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74807105P | 2005-12-07 | 2005-12-07 | |
| US85524906P | 2006-10-30 | 2006-10-30 | |
| PCT/EP2006/068924 WO2007065808A2 (en) | 2005-12-07 | 2006-11-27 | Neuropeptide-2 receptor-agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE549350T1 true ATE549350T1 (de) | 2012-03-15 |
Family
ID=37964711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06830133T ATE549350T1 (de) | 2005-12-07 | 2006-11-27 | Neuropeptid-2-rezeptor-agonisten |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7642244B2 (de) |
| EP (1) | EP1962959B1 (de) |
| JP (1) | JP5000663B2 (de) |
| KR (1) | KR101059602B1 (de) |
| AR (1) | AR057222A1 (de) |
| AT (1) | ATE549350T1 (de) |
| AU (1) | AU2006324076A1 (de) |
| BR (1) | BRPI0619573A2 (de) |
| CA (1) | CA2630649A1 (de) |
| EC (1) | ECSP088511A (de) |
| ES (1) | ES2381497T3 (de) |
| IL (1) | IL191636A (de) |
| MA (1) | MA30142B1 (de) |
| NO (1) | NO20082445L (de) |
| NZ (1) | NZ568772A (de) |
| RU (2) | RU2430108C2 (de) |
| TW (1) | TWI321474B (de) |
| WO (1) | WO2007065808A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010069242A (ko) * | 2000-09-05 | 2001-07-25 | 양우용 | 저주파 물리치료 겸용 혈압 강하기 |
| ES2381497T3 (es) * | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Agonistas del receptor del neuropéptido-2 |
| US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| WO2010052144A2 (en) * | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
| WO2011002066A1 (ja) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | ペプチド及びその用途 |
| EP2477643A1 (de) * | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | V2-rezeptoragonisten mit langzeitwirkung |
| JP2013507414A (ja) * | 2009-10-13 | 2013-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| CN103282054A (zh) * | 2011-01-03 | 2013-09-04 | 弗·哈夫曼-拉罗切有限公司 | 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物 |
| EP3488857B9 (de) | 2012-03-22 | 2023-10-04 | Novo Nordisk A/S | Zusammensetzungen von glp-1-peptiden und herstellung davon |
| CN104428006B (zh) | 2012-07-04 | 2017-09-08 | 弗·哈夫曼-拉罗切有限公司 | 共价连接的抗原‑抗体缀合物 |
| KR20150030755A (ko) | 2012-07-04 | 2015-03-20 | 에프. 호프만-라 로슈 아게 | 항-바이오틴 항체 및 사용 방법 |
| ES2600154T3 (es) | 2012-07-04 | 2017-02-07 | F. Hoffmann-La Roche Ag | Anticuerpos antiteofilina y métodos de uso |
| WO2015071356A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
| MX369818B (es) | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
| US10561737B2 (en) | 2014-01-03 | 2020-02-18 | Hoffmann-La Roche Inc. | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| MX2016008191A (es) | 2014-01-03 | 2017-11-16 | Hoffmann La Roche | Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente. |
| CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
| MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AU2016275735B2 (en) | 2015-06-12 | 2020-02-06 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| AUPO029096A0 (en) | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
| US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| WO2004066966A2 (en) | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
| PT1620118E (pt) | 2003-04-08 | 2014-10-16 | Yeda Res & Dev | Fármacos peguilados de modo reversível |
| CA2545408A1 (en) | 2003-11-25 | 2005-06-16 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| WO2005080424A2 (en) | 2004-02-23 | 2005-09-01 | Rheoscience A/S | Peptide yy analogues |
| US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| WO2006091505A2 (en) | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Neuropeptide y receptor agonists |
| ES2381497T3 (es) * | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Agonistas del receptor del neuropéptido-2 |
| WO2007085887A1 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Pyy agonists and uses thereof |
-
2006
- 2006-11-27 ES ES06830133T patent/ES2381497T3/es active Active
- 2006-11-27 JP JP2008543768A patent/JP5000663B2/ja not_active Expired - Fee Related
- 2006-11-27 CA CA002630649A patent/CA2630649A1/en not_active Abandoned
- 2006-11-27 KR KR1020087016291A patent/KR101059602B1/ko not_active IP Right Cessation
- 2006-11-27 EP EP06830133A patent/EP1962959B1/de active Active
- 2006-11-27 RU RU2008127265/04A patent/RU2430108C2/ru not_active IP Right Cessation
- 2006-11-27 NZ NZ568772A patent/NZ568772A/en not_active IP Right Cessation
- 2006-11-27 AU AU2006324076A patent/AU2006324076A1/en not_active Abandoned
- 2006-11-27 WO PCT/EP2006/068924 patent/WO2007065808A2/en active Application Filing
- 2006-11-27 BR BRPI0619573-3A patent/BRPI0619573A2/pt not_active IP Right Cessation
- 2006-11-27 AT AT06830133T patent/ATE549350T1/de active
- 2006-12-01 US US11/607,230 patent/US7642244B2/en not_active Expired - Fee Related
- 2006-12-04 TW TW095145032A patent/TWI321474B/zh not_active IP Right Cessation
- 2006-12-05 AR ARP060105368A patent/AR057222A1/es active IP Right Grant
-
2008
- 2008-05-22 IL IL191636A patent/IL191636A/en not_active IP Right Cessation
- 2008-05-28 NO NO20082445A patent/NO20082445L/no not_active Application Discontinuation
- 2008-06-06 EC EC2008008511A patent/ECSP088511A/es unknown
- 2008-07-01 MA MA31085A patent/MA30142B1/fr unknown
-
2009
- 2009-08-06 US US12/536,688 patent/US8268784B2/en not_active Expired - Fee Related
-
2011
- 2011-02-15 RU RU2011105310/04A patent/RU2011105310A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006324076A1 (en) | 2007-06-14 |
| IL191636A (en) | 2012-10-31 |
| KR101059602B1 (ko) | 2011-08-25 |
| JP5000663B2 (ja) | 2012-08-15 |
| EP1962959A2 (de) | 2008-09-03 |
| NZ568772A (en) | 2010-05-28 |
| CA2630649A1 (en) | 2007-06-14 |
| EP1962959B1 (de) | 2012-03-14 |
| TWI321474B (en) | 2010-03-11 |
| IL191636A0 (en) | 2008-12-29 |
| ES2381497T3 (es) | 2012-05-28 |
| RU2008127265A (ru) | 2010-01-20 |
| JP2009518349A (ja) | 2009-05-07 |
| MA30142B1 (fr) | 2009-01-02 |
| ECSP088511A (es) | 2008-07-30 |
| US20070135351A1 (en) | 2007-06-14 |
| AR057222A1 (es) | 2007-11-21 |
| TW200806311A (en) | 2008-02-01 |
| WO2007065808A3 (en) | 2007-08-02 |
| US7642244B2 (en) | 2010-01-05 |
| BRPI0619573A2 (pt) | 2011-10-04 |
| KR20080082672A (ko) | 2008-09-11 |
| US20100137223A1 (en) | 2010-06-03 |
| NO20082445L (no) | 2008-09-03 |
| WO2007065808A2 (en) | 2007-06-14 |
| RU2011105310A (ru) | 2012-08-20 |
| US8268784B2 (en) | 2012-09-18 |
| RU2430108C2 (ru) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten | |
| DE602006007563D1 (de) | Agonisten | |
| EP1931352A4 (de) | Tlr-agonisten | |
| DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
| DK3354273T3 (da) | Melanocortinreceptorligander | |
| EP1959959A4 (de) | Morpholin-carboxamid-prokineticin-rezeptor-antagonisten | |
| DK1928882T3 (da) | (s)-n-methylnaltrexon | |
| DK1856054T3 (da) | Pyrazolylcarboxanilider | |
| CR9974A (es) | Gavión | |
| EP1981902A4 (de) | Nogo-rezeptorantagonisten | |
| DE602006020447D1 (de) | Niacin-rezeptoragonisten, zusammensetzungen mit de | |
| DK1989196T3 (da) | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister | |
| ATE549324T1 (de) | Tetrahydrobenzoxazine | |
| BRPI0807911A2 (pt) | Agonistas de alfa2c adrenorreceptor | |
| DK1870409T3 (da) | Benzimidazolforbindelser | |
| ES1064680Y (es) | Estructura portante de receptor | |
| DE112006002964A5 (de) | Zweirichtungsreflektanzverteilungsmessgerät | |
| DE602006021285D1 (de) | Mikrotomklinge | |
| ATE485368T1 (de) | Hiv - impfung | |
| DK1904404T3 (da) | Mærkede uorganiske additiver | |
| DE502005005839D1 (de) | Feldgeerät | |
| DE502006002822D1 (de) | Ges | |
| DE502006000445D1 (de) | Mulchmähdeck | |
| DE102005052834B8 (de) | Punktschweißklebverbindung | |
| AT501523A3 (de) | Estrich |